quinestrol
Trade name: estrovis
Approved
Apr 26, 1996
Quinestrol is a synthetic estrogen that is effective in hormone replacement therapy. It is a 3-cyclopentyl ether of ethynyl estradiol. After gastrointestinal absorption, it is stored in adipose tissue, where it is slowly released and metabolized in the liver to its active form, ethinyl estradiol. Quinestrol has found limited use in suppressing lactation in postpartum women and, in combination with synthetic progestogens, as contraceptive therapy, although additional studies are needed for both applications. Estrogens diffuse into their target cells and interact with a protein receptor (the estrogen receptor). Estrogen interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary. The combination of an estrogen with a progestin suppresses the hypothalamic-pituitary system, decreasing the secretion of gonadotropin-releasing hormone (GnRH). — NCATS
Clinical trial activity
0 trials · 0 clinical orgs · 2 marketing orgs
Timeline
1990s
- Apr 26, 1996
Parke-Davis — Earliest FDA Approval
- Apr 26, 1996
Parke-Davis — NDA Organization
- Apr 26, 1996
Warner Lambert — NDA Secondary Org
Indications
Approved for
Mechanism of action
- Estrogen receptorAGONIST
Estrogen receptor agonist
Approval history
- approvedApr 26, 1996
Chemistry & pharmacology
SMILES
C[C@]12CC[C@H]3[C@@H](CCC4=CC(OC5CCCC5)=CC=C34)[C@@H]1CC[C@@]2(O)C#C- Mol. weight
- 364.5204 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Discontinued
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaQuinestrol ↗
- NCATSJR0N7XD5GZ ↗
- ChEMBLCHEMBL1201165 ↗
Also known as
- 17-alpha-ethinylestradiol 3-cyclopentyl ether
- 17-alpha-ethinylestradiol 3-cyclopentyl ether
- 17alpha-ethynylestradiol 3-cyclopentyl ether
- 17alpha-ethynylestradiol 3-cyclopentyl ether
- eston
- eston
- estradiol-17-beta 3-cyclopentyl ether
- estradiol-17-beta 3-cyclopentyl ether
- estrovis
- estrovis
- estrovis
- estrovis
- estrovis
- estrovis 4000
- estrovis 4000
- estrovister
- estrovister
- estrovister
- ethinyl estradiol 3-cyclopentyl ether
- ethinyl estradiol 3-cyclopentyl ether
- plestrovis
- plestrovis
- plestrovis
- quilea
- quilea
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrol
- quinestrolo
- quinestrolo
- quinestrolum
- quinestrolum
- w-3566
- w-3566
Organizations
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Parke-Davis | For profit | SYN | Apr 26, 1996 |
| Parke-Davis | For profit | NDA | Apr 26, 1996 |
| Warner Lambert | For profit | NDA2 | Apr 26, 1996 |